Prague Med. Rep. 2023, 124, 230-241

Effect of Convalescent Plasma Therapy on Mortality and Viral Load in Severely Ill Patients with COVID-19

Jan Moravec1, Martin Müller1, Petr Turek2, Michal Moravec1, Tomáš Nejtek1, Roman Zazula1

1Department of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
2Department of Blood Transfusion, Thomayer University Hospital, Prague, Czech Republic

Received February 27, 2023
Accepted August 27, 2023

The use of convalescent plasma (CP) appeared to be a promising, easily available and safe way of treatment of severe COVID-19 at the onset of the pandemic in early 2020. Conducted in 2020 and 2021, our study of 52 severely to critically ill COVID-19 patients who received CP plasma as a treatment and of 97 controls found no difference in 30-day or 90-day mortality rates. A significant viral load drop in most patients (4.7 log10 [p<0.001] copies/ml) was observed following CP administration. Retrospective analysis of selected inflammatory markers and immunoglobulins showed higher C-reactive protein levels among the study group, and their decrease on Day 7.


This study was supported by the Ministry of Health of the Czech Republic, grant no. NU22-A-123, and by MH CZ – DRO (Thomayer University Hospital – TUH, 00064190).


19 live references